id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-330550-cxdrac0o	Canonico, Mario Enrico	The tug-of-war between coagulopathy and anticoagulant agents in patients with COVID-19	2020-05-08		.txt	text/plain	917	49	35	Of note, anticoagulant treatment was associated with decreased mortality in severely affected COVID-19 patients. These drugs include antiviral agents (e.g. atazanavir, lopinavir/ritonavir, remdesivir, favipiravir, ribavirin and interferon-b), drugs used for autoimmune disease (e.g. hydroxychloroquine and chloroquine), and anti-cytokine treatments (e.g. tocilizumab and arilumab). Specifically, the levels of dicumarolic agents are increased when coadministred with atazanavir, via CYP2C9 inhibition, while they are decreased with lopinavir/ritonavir and ribavirin via CYP2C9 induction . Nowadays, non-vitamin K antagonist oral anticoagulants (NOACs) are the preferred choice in clinical practice, with a better effective and safety profile compared with dicumarolic agents; however, the risk of DDIs in patients treated for COVID-19 is not negligible. Direct Xa inhibitors, such as apixaban, rivaroxaban, and edoxaban, are contraindicated when coadministered with antiviral agents, because the inhibition of CYP3A4 (e.g. atazanavir and lopinavir) and a P-gp (e.g. ritonavir) increases their serum concentration by two-fold. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy	./cache/cord-330550-cxdrac0o.txt	./txt/cord-330550-cxdrac0o.txt